Tvardi Therapeutics Inc (TVRD) USD0.001

Sell:$26.93Buy:$30.00$1.52 (5.09%)

Prices delayed by at least 15 minutes
Sell:$26.93
Buy:$30.00
Change:$1.52 (5.09%)
Prices delayed by at least 15 minutes
Sell:$26.93
Buy:$30.00
Change:$1.52 (5.09%)
Prices delayed by at least 15 minutes

Company Information

About this company

Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Key people

Imran Alibhai
Chief Executive Officer, Director
Dan Conn
Chief Financial Officer
Jeffrey Larson
Senior Vice President - Research & Development
Stephen O'Brien
Vice President - Finance, Corporate Controller
Yixin Chen
Vice President - Chemistry, Manufacturing and Controls
John Kauh
Chief Medical Officer
Sujal A. Shah
Independent Chairman of the Board
Wallace Hall
Independent Director
Susan Shiff
Independent Director
Cynthia Smith
Independent Director
Shaheen Wirk
Independent Director
Click to see more

Key facts

  • EPIC
    TVRD
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US1407553072
  • Market cap
    $288.88m
  • Employees
    10
  • Shares in issue
    9.36m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.